Portfolio News
Sofinnova MD Start
ELSAN partners with MD Start III to accelerate medtech innovation
This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
Related Strategy
MD StartRelated Deal lead
Anne OsdoitThis collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
June 25, 2020 - PARIS, France -
ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinnova MD START III acceleration fund. Through this partnership, ELSAN becomes an investor in the acceleration fund co-created and managed by Sofinnova Partners, a leading European venture capital firm, and offers its healthcare practitioners the means to accelerate the development of their medical device innovations for the benefit of patients.
"We are delighted that ELSAN is joining Sofinnova MD Start III as a community of clinical investigators and experts," commented Anne Osdoit, Partner at Sofinnova Partners.
Related News
Nitrase Therapeutics announces the appointment of three industry veterans to its Board of Directors
Mediar Therapeutics enters into a collaboration and option agreement with Ono Pharma to develop novel treatments for fibro-inflammatory diseases
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
HAYA Therapeutics receives FDA Fast Track Designation for HTX-001
Moon Surgical and KARL STORZ Announce Strategic Commercial Collaboration to Advance Scalable Surgery